Wegovy Pill Shows Greater Weight Loss Than Foundayo in Novo Study

In the competitive landscape of oral GLP-1 medications for obesity, Novo Nordisk has released data from a cross-trial comparison highlighting its Wegovy pill's advantages over Eli Lilly's newly approved Foundayo. The analysis, known as the ORION study, indicates that Novo's 25 mg dose of oral semaglutide produced 3.2 percentage points more weight loss than Lilly's 36 mg orforglipron, regardless of whether patients stayed on treatment. This finding underscores the growing rivalry between the two pharma giants as they vie to influence prescribing patterns in the emerging oral GLP-1 market.

Understanding the ORION Study: Key Findings on Weight Loss and Tolerability

The ORION study provides a population-adjusted indirect treatment comparison using data from Novo Nordisk and Eli Lilly's separate phase 3 clinical trials. It was not a head-to-head trial and did not generate new clinical data, but it offers valuable insights into comparative efficacy and safety profiles.

Central to the results: patients on the Wegovy pill experienced greater weight loss than those on Foundayo. Specifically, the 25 mg oral semaglutide dose outperformed the 36 mg orforglipron dose by 3.2 percentage points in weight reduction. Additionally, tolerability favored Wegovy, with patients on orforglipron (under the brand name Foundayo) facing roughly 14 times the odds of stopping treatment due to gastrointestinal side effects and four times the odds of discontinuing due to any adverse event.

These outcomes are particularly relevant for obesity management, where sustained weight loss and adherence are critical. Gastrointestinal issues, such as nausea, vomiting, and diarrhea, are common with GLP-1 receptor agonists, making tolerability a key factor in real-world effectiveness.

Mechanisms Behind the Drugs: How Oral Semaglutide and Orforglipron Work

Both medications belong to the GLP-1 receptor agonist class, which mimics the glucagon-like peptide-1 hormone to regulate blood sugar, slow gastric emptying, and reduce appetite. Oral semaglutide (Wegovy pill) is a modified version of semaglutide, previously successful in injectable forms like Ozempic and Wegovy injections. It requires specific absorption enhancers to survive stomach acid, enabling once-daily dosing.

Orforglipron (Foundayo), a non-peptide GLP-1 agonist, represents Eli Lilly's innovation in small-molecule design, potentially offering easier manufacturing and stability. Despite these differences, the ORION data suggests semaglutide's formulation may yield superior weight loss and better GI tolerability in the compared populations.

Study Methodology and Acknowledged Limitations

The ORION study adjusted for baseline body weight, sex, and glycemic status to enable the indirect comparison. However, Novo Nordisk transparently noted limitations: other unaccounted factors may influence results, differences in trial designs could affect comparability, and the low number of adverse events means tolerability findings should be interpreted cautiously.

Novo plans to present the full ORION findings at the Obesity Medicine Association's annual conference in San Diego on April 10. This peer-reviewed setting will allow further scrutiny, emphasizing the study's role as supportive evidence rather than definitive proof.

"Since there are no head-to-head trials comparing oral semaglutide for obesity to orforglipron, this indirect treatment comparison from the ORION study provides important information that can be used during the shared decision-making process," said Robert F. Kushner of Northwestern Feinberg School of Medicine.

Patient Preference: Insights from the OPTIC Study

Complementing ORION, Novo's OPTIC study surveyed 800 U.S. adults in October and November 2025—before Foundayo's approval. Using hypothetical profiles, 84% (four out of five respondents) preferred Wegovy's profile over Foundayo's. While the profiles may not match final FDA-approved labeling, this signals strong hypothetical appeal for Wegovy's efficacy-tolerability balance.

For patients, preference studies like OPTIC highlight how real-world factors like side effects and dosing convenience influence choices. Tools like Shotlee can assist in tracking personal responses to such medications, helping monitor weight loss progress, side effects, and adherence.

Dosing Differences: Convenience vs. Protocol

A major differentiator lies in administration. Foundayo has no food or timing restrictions, allowing flexible integration into daily routines. Lilly CEO Dave Ricks emphasized this convenience to CNBC, positioning it as patient-friendly.

In contrast, the Wegovy pill must be taken first thing each morning with a small sip of water, followed by fasting for at least half an hour. Novo CEO Mike Doustdar countered concerns in a March CNBC interview, stating it was "absolutely not the case" that these requirements would deter patients.

These protocols reflect formulation needs: semaglutide's peptide nature demands strict conditions for optimal absorption, while orforglipron's design offers more leniency. Patients should weigh lifestyle fit when discussing options with providers.

Market Milestones and Accessibility

The Wegovy pill launched in the U.S. market at the start of the year and has reached more than 600,000 patients, demonstrating rapid uptake amid high demand for oral alternatives to injections.

Foundayo received FDA approval earlier this week via its National Priority Voucher program—294 days ahead of the standard review deadline. The agency noted it as the fastest approval for any new molecular entity since 2002, accelerating access to this innovation.

Both companies set entry-level pricing at $149 a month for the lowest doses for uninsured patients, leveling the field on affordability and intensifying competition on efficacy and tolerability.

Implications for Patients and Providers in Obesity Treatment

For individuals with obesity, these developments expand oral GLP-1 options beyond injections, potentially improving adherence for those averse to needles. The ORION and OPTIC data suggest Wegovy may offer better weight loss and tolerability, but individual responses vary based on factors like comorbidities, age, and lifestyle.

Patients considering these should consult healthcare providers to review personal risks, including gastrointestinal side effects common to GLP-1s (nausea in up to 20-30% of users, per phase 3 data). Discuss baseline health, potential drug interactions, and monitoring plans. Compared to alternatives like tirzepatide (Zepbound/Mounjaro), oral GLP-1s provide convenience but may differ in potency.

Safety Considerations with Oral GLP-1 Medications

Both drugs share class risks: pancreatitis, gallbladder issues, and thyroid tumors (boxed warning for semaglutide). ORION's higher GI discontinuation for Foundayo warrants caution for sensitive patients. Long-term data is emerging, but phase 3 trials showed sustained benefits with proper management.

• Monitor for dehydration from GI effects.
• Start low, titrate slowly to minimize side effects.
• Combine with diet/exercise for optimal results.

Key Takeaways: What This Means for Metabolic Health

• Wegovy's oral semaglutide (25 mg) showed 3.2% greater weight loss than Foundayo's orforglipron (36 mg) in ORION cross-trial analysis.
• Foundayo users had 14x higher GI discontinuation odds, 4x for any adverse event.
• 84% preferred Wegovy's profile in OPTIC survey.
• Dosing: Wegovy requires morning fasting protocol; Foundayo is restriction-free.
• Both priced at $149/month entry-level; rapid market entries signal oral GLP-1 growth.

In summary, while awaiting head-to-head trials, ORION equips shared decision-making with comparative insights. Patients stand to benefit from this competition driving innovation in peptide therapy and metabolic health.

Conclusion: Navigating Oral GLP-1 Choices

The Novo vs. Lilly showdown elevates oral semaglutide and orforglipron as frontrunners. Preserve heart health discussions by focusing on evidence-based options—consult your doctor to determine if Wegovy pill or Foundayo aligns with your goals. Stay informed on updates from conferences like Obesity Medicine Association for evolving data.